Conferences - Results from #8580

SUO 2015 Surgical Coaching for Performance Improvement - Session Highlights December 3, 2015

SUO 2015 Putting the “PATIENT” into Patient-centered Outcomes Research Prioritization - Session Highlights December 3, 2015

SUO 2015 Emerging therapies for patients with bladder cancer - Session Highlights December 3, 2015

SUO 2015 - New approaches to adjuvant therapy for muscle-invasive bladder cancer - Session Highlights December 3, 2015

SUO 2015 - Venous thromoboembolism following nephrectomy: thirty day incidence and risk factors from national multi-institutional data - Poster Session Highlights December 3, 2015

SUO 2015 - Systemic Therapy in UTUC: Chemotherapy in the renal impaired - Session Highlights December 3, 2015

SUO 2015 - Systemic Therapy in UTUC: The Role of Checkpoint Blockade Therapies - Session Highlights December 3, 2015

SUO 2015 - Systemic Therapy in UTUC: Neoadjuvant Treatment: Standard of Care? - Session Highlights December 3, 2015

SUO 2015 Lynch Syndrome in UTUC: Significance, Screening, and Surveillance - Session Highlights December 3, 2015

SUO 2015 - Variant Morphology in Bladder Cancer: Updates and Controversies - Session Highlights December 3, 2015

SUO 2015 Aggressive Variant Prostate Carcinomas: “Beyond Morphologic Characterization” - Session Highlights December 3, 2015

SUO 2015 - Intermediate Atypical Carcinoma: A New CRPC Entity - Session Highlights December 2, 2015

Clinical outcomes in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with abiraterone acetate (ABI) stratified by prognosis October 14, 2015

The Prostate Cancer Registry: First results from an international, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC) October 14, 2015

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. A retrospective “Real Life” analysis of activity and safety October 14, 2015

ASCO - Poster: Randomized phase-2 study of sipuleucel-T with or without radium-223 in men with asymptomatic/minimally symptomatic bone-metastatic castrate-resistant prostate cancer June 18, 2015

ASCO - Poster: Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients June 11, 2015

ASCO - TROG 03.06 and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial - Session Highlights June 10, 2015

ASCO - A phase III protocol of androgen suppression and radiotherapy vs. AS and RT followed by chemotherapy with docetaxel and prednisone for localized, high-risk prostate cancer - Session Highlights June 9, 2015

ASCO - First-ever evidence shows adjuvant chemotherapy improves overall survival in high-risk, localized prostate cancer - Session Highlights June 4, 2015

Page 430 of 507